Balancing Hyperkalemia Risks with Clinical Benefits of Renin-Angiotensin-Aldosterone Inhibitors/Mineralocorticoid Receptor Antagonists Blockade: It's Apples and Oranges.

Leon, Silvia J; Tangri, Navdeep

Leon, Silvia J; Tangri, Navdeep.

Affiliation

Leon SJ; Chronic Disease Innovation Centre, Seven Oaks General Hospital, Winnipeg, Canada.
Tangri N; Department of Internal Medicine, Max Rady College of Medicine, University of Manitoba, Winnipeg, Canada.

Kidney360 ; 3(8): 1442-1444, 2022 08 25.

Article in En | MEDLINE | ID: mdl-36176652

Subject(s)

Hyperkalemia; Mineralocorticoid Receptor Antagonists; Aldosterone; Angiotensin Receptor Antagonists/adverse effects; Angiotensins; Antihypertensive Agents; Humans; Hyperkalemia/chemically induced; Mineralocorticoid Receptor Antagonists/adverse effects; Mineralocorticoids; Renin

Key words

ACE inhibitors; ARB; MRA; RAAS inhibitor; chronic kidney disease; finerenone; hyperkalemia; potassium binders

Fulltext

Add to My VHL

XML

PubMed Links

Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Mineralocorticoid Receptor Antagonists / Hyperkalemia Type of study: Etiology_studies / Risk_factors_studies Limits: Humans Language: En Journal: Kidney360 Year: 2022 Document type: Article Affiliation country: Canada

Fulltext

Add to My VHL

XML

PubMed Links

Search on Google